MX349563B - Formulacion farmaceutica de fenofibrato nanonizado. - Google Patents

Formulacion farmaceutica de fenofibrato nanonizado.

Info

Publication number
MX349563B
MX349563B MX2011006721A MX2011006721A MX349563B MX 349563 B MX349563 B MX 349563B MX 2011006721 A MX2011006721 A MX 2011006721A MX 2011006721 A MX2011006721 A MX 2011006721A MX 349563 B MX349563 B MX 349563B
Authority
MX
Mexico
Prior art keywords
nanonised
fenofibrate
pharmaceutical formulation
relates
preparing same
Prior art date
Application number
MX2011006721A
Other languages
English (en)
Other versions
MX2011006721A (es
Inventor
Pascal Oury
Catherine Herry
Original Assignee
Ethypharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Sa filed Critical Ethypharm Sa
Publication of MX2011006721A publication Critical patent/MX2011006721A/es
Publication of MX349563B publication Critical patent/MX349563B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Abstract

La invención se refiere a una formulación farmacéutica de fenofibrato nanonizado, a un método para preparar el mismo, y los usos del mismo.
MX2011006721A 2008-12-24 2009-12-24 Formulacion farmaceutica de fenofibrato nanonizado. MX349563B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0859064A FR2940118B1 (fr) 2008-12-24 2008-12-24 Formulation pharmaceutique de fenofibrate nanonise
PCT/EP2009/067915 WO2010081623A1 (fr) 2008-12-24 2009-12-24 Formulation pharmaceutique de fenofibrate nanonise

Publications (2)

Publication Number Publication Date
MX2011006721A MX2011006721A (es) 2011-09-01
MX349563B true MX349563B (es) 2017-08-02

Family

ID=40821673

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011006721A MX349563B (es) 2008-12-24 2009-12-24 Formulacion farmaceutica de fenofibrato nanonizado.

Country Status (9)

Country Link
US (1) US20110311619A1 (es)
EP (1) EP2381927B1 (es)
AU (1) AU2009337766B2 (es)
CA (1) CA2747269C (es)
ES (1) ES2607109T3 (es)
FR (2) FR2940118B1 (es)
IL (1) IL213711A (es)
MX (1) MX349563B (es)
WO (1) WO2010081623A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013064853A1 (en) * 2011-11-05 2013-05-10 Lupin Atlantis Holdings, S.A. Reduced dose oral pharmaceutical compositions of fenofibrate
US9439860B2 (en) 2012-06-25 2016-09-13 Mylan, Inc. Fenofibrate formulation
EP2863890A4 (en) * 2012-06-25 2015-12-09 Mylan Inc FORMULATION OF FENOFIBRATE
US8722083B2 (en) 2012-06-25 2014-05-13 Mylan, Inc. Fenofibrate formulation
WO2014091318A1 (en) 2012-12-11 2014-06-19 Lupin Atlantis Holdings, S.A. Reduced dose pharmaceutical compositions of fenofibrate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2602423B1 (fr) 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
US6682761B2 (en) * 2000-04-20 2004-01-27 Rtp Pharma, Inc. Water-insoluble drug particle process
US20030224058A1 (en) 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP2228060A1 (en) * 2002-05-03 2010-09-15 Skyepharma Canada Inc. Oral dosage forms comprising fenofibrate
KR100767349B1 (ko) * 2006-08-01 2007-10-17 삼천당제약주식회사 페노피브레이트를 함유하는 경구용 약제 조성물 및 그의제조방법

Also Published As

Publication number Publication date
CA2747269C (fr) 2016-08-16
AU2009337766B2 (en) 2014-09-25
FR2940086A1 (fr) 2010-06-25
CA2747269A1 (fr) 2010-07-22
AU2009337766A1 (en) 2011-07-14
EP2381927B1 (fr) 2016-09-21
MX2011006721A (es) 2011-09-01
WO2010081623A1 (fr) 2010-07-22
IL213711A0 (en) 2011-07-31
ES2607109T3 (es) 2017-03-29
FR2940118B1 (fr) 2013-08-09
EP2381927A1 (fr) 2011-11-02
FR2940086B1 (fr) 2011-03-11
IL213711A (en) 2016-02-29
FR2940118A1 (fr) 2010-06-25
US20110311619A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MX2013001045A (es) Organoide hepatico, sus usos y metodo de cultivo para obtenerlos.
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
MX364229B (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
HK1148202A1 (en) Pharmaceutical solutions, process of preparation and therapeutic uses
MX341825B (es) Compuestos de heteroarilo y usos de los mismos.
WO2012003450A3 (en) Biomatrix scaffolds
WO2011130615A3 (en) Preparation of lacosamide
MX2013008737A (es) Formas de dosificacion oral para tasocitinib que comprende liberacion modificada.
ZA201001015B (en) (Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
IL204556A0 (en) (cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
MX2012004780A (es) Inhibidores de akt.
TW201144301A (en) Processes for preparing linezolid
ZA201301463B (en) Pharmaceutical compositions for calonolides,their derivatives and analogues,and process for producing the same
IN2012DN02793A (es)
EP2241569A4 (en) THIENOPYRIDAZINE COMPOUNDS, PREPARATIONS THEREOF, PHARMACEUTICAL COMPOSITIONS AND USES
UA107476C2 (uk) Фармацевтична субстанція на основі мітохондріально адресованих антиоксидантів
IN2012DN03404A (es)
MX348786B (es) Agentes osmoticos de polisacarido esterificado.
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
IL211062A0 (en) Pharmaceutical uses of lanosta-8,24-dien-3-ols
JO2857B1 (en) Vinyl pipers with modified activity of tumor-resistant TNF
AP2012006352A0 (en) AzabicycloÄ3.1.0Ühex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same.
WO2010139411A3 (de) 17β-ALKYL-17α-OXY-ESTRATRIENE
MX2013005624A (es) Nuevos derivados de indolizina, su preparacion y su aplicacion en terapeutica.

Legal Events

Date Code Title Description
FG Grant or registration